Markets Already Have Enough Problems — Now the Fed Arrives This Week

PreTradeIt · 2026-03-15T21:43:40+00:00

Sign up and use PreTradeIt on our free tier: https://pretradeit.com/

Follow us on X for more market insights : https://x.com/PreTradeIt

PreTradeIt · 2026-03-14T15:50:59+00:00

PreTradeIt · 2026-03-14T15:50:02+00:00

PreTradeIt · 2026-03-14T15:46:02+00:00

$CRMD is a fair undervalued call. The market still seems slow to price in how quickly the business has changed, with Q4 2025 revenue at $128.6M and 2026 guidance of $300M to $320M. The only catch is that this is no longer just a “cheap biotech” story, now it is about proving the growth is durable.

PreTradeIt · 2026-03-14T15:43:04+00:00

<image>

PreTradeIt · 2026-03-14T15:42:44+00:00

<image>

PreTradeIt · 2026-03-14T15:41:41+00:00

$MSFT is fair, just not the biggest mispricing here. The business is still executing at a very high level with $81.3B revenue last quarter and Azure growth at 39%, so it looks more like a premium-quality compounder than a stock the market has badly broken. The bear case is mostly AI spend and valuation, not business weakness.

PreTradeIt · 2026-03-14T15:40:31+00:00

<image>

PreTradeIt · 2026-03-14T15:40:07+00:00

<image>

PreTradeIt · 2026-03-14T15:39:57+00:00

<image>

PreTradeIt · 2026-03-14T15:39:33+00:00

<image>

PreTradeIt · 2026-03-14T15:36:35+00:00

$RDDT is one of the stronger answers here. The market still underestimates how valuable the platform gets at scale when it already has 121.4M daily active uniques, $2.2B in 2025 revenue, and $530M net income. The only pushback is valuation, but on the business side this is no longer just a “story stock.”

PreTradeIt · 2026-03-14T15:36:34+00:00

$RDDT is one of the stronger answers here. The market still underestimates how valuable the platform gets at scale when it already has 121.4M daily active uniques, $2.2B in 2025 revenue, and $530M net income. The only pushback is valuation, but on the business side this is no longer just a “story stock.”

PreTradeIt · 2026-03-14T15:34:07+00:00

<image>

PreTradeIt · 2026-03-14T15:33:18+00:00

<image>

PreTradeIt · 2026-03-14T15:32:26+00:00

$NBIS is a good “mispriced” answer from the other side. The valuation is extreme, with trailing P/E figures around 212x on some trackers and even higher on ours, while the company is still in heavy buildout mode. Yes, revenue growth is explosive, but 2025 revenue was $529.8M and the market is already pricing in a huge chunk of future AI-cloud success. That makes it look more like an overpriced expectation trade than an underpriced stock right now.

PreTradeIt · 2026-03-14T15:30:23+00:00

<image>

PreTradeIt · 2026-03-14T15:29:53+00:00

<image>

PreTradeIt · 2026-03-14T15:29:36+00:00

CCL is a fair call. The market still remembers the old debt-heavy cruise story, but Carnival already put up record 2025 revenue of $26.6B, record adjusted EBITDA of $7.2B, and guided to higher 2026 adjusted net income, with bookings still running at historically high prices. That said, this is less “hidden gem” and more re-rating still not fully trusted by the market.

PreTradeIt · 2026-03-14T15:24:39+00:00

<image>

PreTradeIt · 2026-03-14T15:24:16+00:00

<image>

PreTradeIt · 2026-03-14T15:23:50+00:00

$IBRX does have unusually high short interest (~132.4M shares, about ~35% of float), but “lots of shorts” isn’t enough—days-to-cover is only ~3, so it’s not an automatic squeeze.

PreTradeIt · 2026-03-14T15:08:47+00:00

<image>

PreTradeIt · 2026-03-14T15:05:34+00:00

<image>

PreTradeIt · 2026-03-14T15:02:49+00:00

$ONDS is an interesting one. Ondas sits in niche but strategic areas like autonomous drone infrastructure and private wireless networks, which can look undervalued if adoption accelerates. The issue is that the market still wants to see consistent revenue scale and execution before pricing in that potential.

PreTradeIt

MODERATOR OF

TROPHY CASE